Neurocrine (NBIX) director granted stock options and RSUs as equity compensation
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NEUROCRINE BIOSCIENCES INC director Gary A. Lyons received new equity awards as part of his compensation. On May 27, 2026, he was granted non-qualified stock options for 2,624 shares of common stock at an exercise price of $155.83 per share, vesting in 12 monthly installments beginning June 27, 2026.
He also received 1,284 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs will vest in full on May 27, 2027. The filing shows these as direct holdings and reflects routine, compensation-related acquisitions rather than open-market buying or selling.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
LYONS GARY A
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restriced Stock Unit | 1,284 | $0.00 | -- |
| Grant/Award | Non-Qualified Stock Option | 2,624 | $0.00 | -- |
Holdings After Transaction:
Restriced Stock Unit — 1,284 shares (Direct, null);
Non-Qualified Stock Option — 2,624 shares (Direct, null)
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs will vest in full on May 27, 2027. Option vests in 12 monthly installments beginning June 27, 2026.
Key Figures
Stock options granted: 2,624 options
Option exercise price: $155.83 per share
RSUs granted: 1,284 RSUs
+5 more
8 metrics
Stock options granted
2,624 options
Non-qualified stock option grant on May 27, 2026
Option exercise price
$155.83 per share
Exercise price for newly granted options
RSUs granted
1,284 RSUs
Restricted Stock Unit grant on May 27, 2026
Option vesting start
June 27, 2026
First of 12 monthly vesting installments
Option expiration
May 27, 2036
Expiration date for non-qualified stock options
RSU vesting date
May 27, 2027
Cliff vesting date when RSUs vest in full
Options held after grant
2,624 options
Total options reported following transaction
RSUs held after grant
1,284 RSUs
Total RSUs reported following transaction
Key Terms
Non-Qualified Stock Option, Restricted Stock Unit, vest, exercise price, +1 more
5 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option grant for 2,624 shares at $155.83 per share"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents the right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
vest financial
"The RSUs will vest in full on May 27, 2027."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "155.8300" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant/award acquisition financial
"transaction_action": "grant/award acquisition" for both equity awards"
FAQ
What equity awards did NBIX director Gary A. Lyons receive in this Form 4?
Gary A. Lyons received non-qualified stock options for 2,624 shares and 1,284 Restricted Stock Units. Both awards relate to Neurocrine Biosciences common stock and are classified as compensation-related grants, not open-market purchases or sales.
What are the vesting terms of Gary Lyons’ Neurocrine (NBIX) stock options?
The non-qualified stock options for 2,624 shares have an exercise price of $155.83 per share. They vest in 12 equal monthly installments starting June 27, 2026, providing a one-year vesting schedule after the grant date.
When do Gary Lyons’ Restricted Stock Units in NBIX fully vest?
The 1,284 Restricted Stock Units granted to Gary Lyons vest in full on May 27, 2027. Each RSU represents the right to receive one share of Neurocrine Biosciences common stock upon vesting, according to the filing footnotes.
Does this NBIX Form 4 show Gary Lyons buying or selling stock on the market?
No, the Form 4 reports compensation-related grants, not market trades. Both the stock options and RSUs are coded as awards or other acquisitions, with no open-market purchase or sale transactions disclosed in this filing.
What exercise price is attached to Gary Lyons’ newly granted NBIX stock options?
The non-qualified stock options carry an exercise price of $155.83 per share. This is the price at which Gary Lyons can purchase Neurocrine Biosciences common stock if he exercises the options after they vest.